Literature DB >> 30209775

Retinal function in eyes with proliferative diabetic retinopathy treated with intravitreal ranibizumab and multispot laser panretinal photocoagulation.

Katharina Messias1, Rafael de Montier Barroso1, Rodrigo Jorge1, Andre Messias2.   

Abstract

PURPOSE: To compare retinal function changes in eyes with proliferative diabetic retinopathy (PDR) after intravitreal ranibizumab (IVR), combined or not with conventional (ETDRS) or multispot laser panretinal (PASCAL) photocoagulation (PRP).
METHODS: This study included laser-naive PDR patients that required PRP. Eyes were randomly and prospectively assigned to receive IVR or IVR combined with PASCAL or EDTRS. PRP was performed at baseline in 1 (PASCAL) or 2 (ETDRS) sessions. In eyes with macular edema, macular short pulse grid laser was associated with IVR at baseline and IVR was repeated monthly or quarterly if neovascularization was detected on angiography. Comprehensive ophthalmological evaluations, including SD-OCT, were performed at baseline and every 4 weeks after treatment. Full-field electroretinography (ERG: extended ISCEV standard) was performed at baseline and at 12, 24 and 48 weeks.
RESULTS: IVR = 13, PASCAL = 15 and ETDRS = 15 eyes finished 48-week follow-up. There was a statistically significant BCVA improvement of 0.1-0.3 logMAR in all groups, and fluorescein angiography leakage area (FLA) reduced in 56%, 73%, and 73% from baseline for ETDRS, IVR and PASCAL, respectively, up to 48 weeks without significant differences between groups (p > 0.05). A significant a- and b-wave amplitudes reduction was observed for dark- and light-adapted ERG for ETDRS and PASCAL, but only minor dark-adapted b-wave reduction was found for IVR, up to 48 weeks. As an example, at week 48, combined response b-wave amplitude reduced in 181.5 ± 31.4 µV, 128.0 ± 27.9 µV and 82.4 ± 15.2 µV for ETDRS, PASCAL and IVR (p < 0.05 each group), respectively. No significant difference was observed between ETDRS and PASCAL for any ERG parameter.
CONCLUSIONS: IVR combined with single or multiple spot PRP causes similar retinal function impairment during 48 weeks of observation, while IVR alone seems to be similarly effective controlling FLA without changing retinal function.

Entities:  

Keywords:  Anti-VEGF; Diabetic retinopathy; Electroretinography; Retinal photocoagulation

Mesh:

Substances:

Year:  2018        PMID: 30209775     DOI: 10.1007/s10633-018-9655-9

Source DB:  PubMed          Journal:  Doc Ophthalmol        ISSN: 0012-4486            Impact factor:   2.379


  26 in total

1.  Panretinal photocoagulation for proliferative diabetic retinopathy: pattern scan laser versus argon laser.

Authors:  Aimee V Chappelow; Kevin Tan; Nadia K Waheed; Peter K Kaiser
Journal:  Am J Ophthalmol       Date:  2011-09-19       Impact factor: 5.258

2.  Preliminary report on effects of photocoagulation therapy. The Diabetic Retinopathy Study Research Group.

Authors: 
Journal:  Am J Ophthalmol       Date:  1976-04       Impact factor: 5.258

3.  ERG and VER findings after laser photocoagulation of the retina.

Authors:  M Moschos
Journal:  Metab Pediatr Syst Ophthalmol       Date:  1982

Review 4.  Vascular endothelial growth factors and angiogenesis in eye disease.

Authors:  A N Witmer; G F J M Vrensen; C J F Van Noorden; R O Schlingemann
Journal:  Prog Retin Eye Res       Date:  2003-01       Impact factor: 21.198

5.  Contrast sensitivity in diabetic retinopathy after panretinal photocoagulation.

Authors:  P K Khosla; V Rao; H K Tewari; A Kumar
Journal:  Ophthalmic Surg       Date:  1994-08

6.  Use of diffusive gradients in thin films and tangential flow ultrafiltration for fractionation of Al(III) and Cu(II) in organic-rich river waters.

Authors:  Paulo S Tonello; André H Rosa; Cassio H Abreu; Amauri A Menegário
Journal:  Anal Chim Acta       Date:  2007-07-26       Impact factor: 6.558

7.  Long-term stability and visual outcome after favorable initial response of proliferative diabetic retinopathy to panretinal photocoagulation.

Authors:  J F Vander; J S Duker; W E Benson; G C Brown; J A McNamara; R B Rosenstein
Journal:  Ophthalmology       Date:  1991-10       Impact factor: 12.079

8.  Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders.

Authors:  L P Aiello; R L Avery; P G Arrigg; B A Keyt; H D Jampel; S T Shah; L R Pasquale; H Thieme; M A Iwamoto; J E Park
Journal:  N Engl J Med       Date:  1994-12-01       Impact factor: 91.245

9.  Panretinal photocoagulation and retinal oxygenation.

Authors:  M B Landers; E Stefansson; M L Wolbarsht
Journal:  Retina       Date:  1982       Impact factor: 4.256

10.  The Effect of Multispot Laser Panretinal Photocoagulation on Retinal Sensitivity and Driving Eligibility in Patients With Diabetic Retinopathy.

Authors:  Mala Subash; Oliver Comyn; Ahmed Samy; Dania Qatarneh; Serafeim Antonakis; Manjit Mehat; James Tee; Tatiana Mansour; Wen Xing; Catey Bunce; Ananth Viswanathan; Gary Rubin; Richard Weleber; Tunde Peto; Louisa Wickham; Michel Michaelides
Journal:  JAMA Ophthalmol       Date:  2016-06-01       Impact factor: 7.389

View more
  3 in total

1.  Comparison of functional changes of retina after subthreshold and threshold pan-retinal photocoagulation in severe non-proliferative diabetic retinopathy.

Authors:  Hongkun Zhao; Lijun Zhou; Kunbei Lai; Minzhong Yu; Chuangxin Huang; Fabao Xu; Cong Li; Lin Lu; Chenjin Jin
Journal:  Lasers Med Sci       Date:  2022-09-07       Impact factor: 2.555

2.  Transient Increase and Delay of Multifocal Electroretinograms Following Laser Photocoagulations for Diabetic Macular Edema.

Authors:  Yoshiaki Shimada; Masayuki Shibuya; Kei Shinoda
Journal:  J Clin Med       Date:  2021-01-19       Impact factor: 4.241

3.  Electroretinogram Changes Following Sequential Panretinal Photocoagulation for Proliferative Diabetic Retinopathy.

Authors:  Hassan Khojasteh; Rasoul Amini Vishte; Ali Mirzajani; Elias Khalili Pour; Fatemeh Bazvand; Hamid Riazi-Esfahani; Masoud Mirghorbani; Bobeck S Modjtahedi
Journal:  Clin Ophthalmol       Date:  2020-03-30
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.